TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PregnanT Moms Measure - Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Pregnant between 12-15 weeks at the start of the study;~2. Healthy as assessed by the Health and Lifestyle questionnaire (P9624 F02);~3. Body mass index:~   * BMI 18,5 - 25 for the lean group~  * BMI ≥ 30 for the obese group;~4. Able to use self-monitoring devices;~5. Voluntary participation;~6. Having given written informed consent;~7. Willing to comply with study procedures;~8. Willingness to share pseudonymised data on measured health parameters with external parties that provide the measuring devices (including MijnEetmeter, Moves and NRC) for reasons of synchronisation with the study database;~9. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data by TNO;~10. Have internet access at home;~11. Subjects should own a Smartphone with Bluetooth that runs either a recent version of iOS or Android.~Exclusion Criteria:~1. Use of concomitant medication;~2. Having a history of medical or surgical events that may significantly affect the study outcome, including physical limitations or cardio-vascular events;~3. Having a (history of a) medical condition that might significantly affect the study outcome as judged by the principal investigator and health and life style questionnaire. This includes diabetes type 1 or 2, gastrointestinal dysfunction, diseases related to inflammation, or a psychiatric disorder;~4. Hypertension: systolic blood pressure \>160 mmHg, diastolic blood pressure \>90 mmHg;~5. Having a pacemaker;~6. Previous pregnancy with medical issues (e.g. pre-eclampsia);~7. Reported slimming or medically prescribed diet;~8. Physical, mental or practical limitations in using computerized systems;~9. Alcohol consumption \> 14 units (drinks)/week;~10. Smoking;~11. Reported unexplained weight loss or gain of \> 2 kg in the three months prior to the pre-study screening / pregnancy;~12. Recent blood donation (\<1 month prior to the start of the study);~13. Not willing to give up blood donation during the study;~14. Personnel of TNO and their partner.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Obese pregnant women (Type: None): 20 obese pregnant women (BMI ≥ 30)
- Lean pregnant women (Type: None): 20 lean pregnant women (BMI 18,5 - 25)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have an active malignancy defined as any of: a) Diagnosis of cancer (excluding basal cell or squamous cell carcinoma of the skin) within 18 months of enrollment; b) Have received treatment for cancer within 18 months (e.g. radiation therapy, chemotherapy, adjuvant therapy); c) Have documented recurrent or metastatic cancer~* Receiving a 3-6 month course of weight-adjusted LMWH for an acute, objectively confirmed, symptomatic VTE (proximal or distal DVT of the lower extremity, proximal DVT of the upper extremity, or PE)~* Age ≥ 18 years~* Life expectancy \> 6 months~* Able to comply with scheduled follow up visits~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Willing to provide written informed consent~Exclusion Criteria:~* Distal DVT of the upper extremity~* Recurrent VTE during the 3-6-month LMWH treatment period~* Major or clinically relevant non-major bleeding during the 3-6 month LMWH treatment period~* Risk of bleeding (e.g. recent neurosurgery, history of intracranial hemorrhage, acute gastroduodenal ulcer, etc.)~* Diagnosis of basal cell and squamous cell carcinoma of the skin or acute Leukemia~* Platelet count \< 50 x 109/L~* Creatinine clearance \<30ml/min (using the modified Cockcroft-Gault formula)~* On hemodialysis~* Known hypersensitivity to heparin, LMWHs, or pork products~* Known contraindication to the use of heparin (e.g. heparin-induced thrombocytopenia)~* Currently participating in another clinical trial involving anticoagulation therapy (with the exception of aspirin)~* Pregnancy or breastfeeding~* On an anticoagulant for a different indication~* Treating physician plans for weight-adjusted LMWH for longer than 3-6 months duration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* EOC patients must be platinum resistant/refractory (see 1.1 for definition) and be considered by the attending physician capable of being treated in this study according to GCP.~* Measurable disease by RECIST criteria or evaluable disease by GCIC criteria~* No prior anthracycline or lenalidomide use, unless the dose received was equal or less than one cycle and the patient did not progress on treatment.~* Subjects must have calculated creatinine clearance \> 60ml/min by Cockcroft-Gault formula during the escalation phase.~* Subjects must have calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula during the expansion phase. See section below, Dosing Regimen, regarding lenalidomide dose adjustment for calculated creatinine clearance \> 30ml/min and \< 60ml/min.~* Understand and voluntarily sign an informed consent form.~* All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.~* Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control.~* No contraindication to anticoagulation~Exclusion Criteria:~* Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).~* Concurrent use of other anti-cancer agents or treatments.~* Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.~* History of thromboembolic event within the last 3 months~* Known hypersensitivity to any component of Avastin

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Type 1 or Type 2 diabetes mellitus.~* Patients who have an expected minimum 50% likelihood of requiring corneal epithelial debridement in the opinion of the Investigator Size of wound should be 8 mm.~* Signed written informed consent by patient or legal guardian.~Exclusion Criteria~* Have current or history of herpetic eye disease in the past 3 years.~* Display evidence of keratitis.~* Have Sjögren's syndrome.~* Have corneal scarring, opacity, or dystrophy.~* Have a history of malignancy.~* Have a history of HIV or AIDs~* Are pregnant or lactating females.~* Are females who can become pregnant.~* Have a known hypersensitivity to the study drug.~* May be regarded as unreliable for the study.~* Have previously participated in this study.~* Experience any complication during the vitrectomy procedure itself, which will exclude the patient from participating in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of eyedrops to the affected eye, identical to the active drug but with no thymosin beta 4 (0.00% thymosin beta 4, w/w), 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
- 1 (Type: ACTIVE_COMPARATOR): There are 2 groups: active drug and placebo. The patients in the active comparator arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quantitative EEG Assessment of Cue-Induced Changes in Brain Activity in Alcohol Use Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, aged 21 to 70.~2. History of heavy drinking: Defined as at least 8 occasions in the past month that individual had at least 5 drinks (males) or 4 drinks (females) in one sitting.~3. The subject must currently not be in treatment for any alcohol use disorder~4. Subject must be able to comprehend and perform study related information and tasks in English and have a willingness to complete study procedures.~5. Subject must be able to provide written informed consent, at time of consent BAC has to be 0.00%.~6. The subject must have the ability to read/speak English~Exclusion Criteria:~1. Severe impairment of sight, smell, or hearing that would result in a significant alteration in the response to alcohol related cues.~2. Currently on a medication used to treat alcoholism or is known to alter EEG activity or responsiveness to cue presentation including acamprosate, anticonvulsants, anticholinergics, antipsychotics, benzodiazepine receptor agonists, beta adrenergic receptor antagonists, and naltrexone.~3. History of any neurological or psychiatric disorder that would result in abnormal EEG activity such as severe brain trauma, seizure disorders, stroke or that would severly alter response to the cue presentation such as schizophrenia or any other psychotic or severe mood disorder.~4. CIWA-AR score of 8 or higher or any history indicating that the subject is at risk for experiencing severe alcohol withdrawal symptoms if her or his drinking is discontinued for any period of time.~5. The subject must not be pregnant. -

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intentional Rounding in Internal Medicine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Signature of informed consent~* Patients who understand Italian~Exclusion Criteria:~* Patients who deny informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intentional Rounding (Type: EXPERIMENTAL): In the centers randomized to Intentional Rounding the ward nurses will have to adopt a new proactive care method towards hospitalized patients
- Control (Type: NO_INTERVENTION): In randomized controlled centers, nurses guarantee the standard care provided by the ward

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participant population will include patients characterized by: nodular/polypoid features, bleeding/ulcerated lesions, excluding face and vulvo-genital lesions.~Exclusion Criteria:~* Participants who are not: currently immunocompromized, on immuno-therapy for other diagnosis, have known inflammatory or autoimmune diseases or are otherwise incapacitated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intralesional IL-2 Injection (Type: EXPERIMENTAL): Two subcutaneous intralesional injections of Aldesleukin, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
- Saline Injection (Type: PLACEBO_COMPARATOR): Two subcutaneous intralesional injections of Saline, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years of age~* Patient is Human Immunodeficiency Virus (HIV) positive~* Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) \<50 copies/milliliter (mL) for at least 3 months while on a KALETRA based regimen~* Patient has been on a KALETRA based regimen for at least 3 months without a change in background antiretroviral therapy~* Patient has no documentation of HIV RNA \>50 copies/mL for at least 3 months while on the KALETRA based regimen~Exclusion Criteria:~* Patient is or plans to become pregnant, or nursing a child~* Patient plans to donate eggs or impregnate/donate sperm~* Patient is receiving Stavudine (d4T) as a component of the background antiretroviral therapy~* Patient is currently receiving a second protease inhibitor in addition to KALETRA~* Patient is currently receiving, or has received in the past twelve weeks, treatment for the management of elevated lipids~* Patient has used another experimental HIV-integrase inhibitor~* Patient has a current (active) diagnosis of acute hepatitis due to any cause~* Patient has used systemic immunosuppressive therapy within one month prior to treatment in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir )
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase IIa L-serine Trial for eAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of early stage Alzheimer's disease as scored by the ClinicalDementia Rating Scale score of 0.5 -1.0 within the 6 months prior to study enrollment.~2. Participants able to provide informed consent.~3. Participants taking NMDA receptor antagonist medications or acetylcholinesterase inhibitor medications must be on a stable dose of these medications for at least 30 days prior to enrolling in this clinical trial.~4. Participants able to consume study gummy chews throughout the course of the clinical trial.~Exclusion Criteria:~1. Diagnosis or previous history of ischemic stroke, astrocytoma, meningioma or oligodendroma.~2. Diagnosis or previous history of any other comorbid diagnosis of neurodegenerative disease including amyotrophic lateral sclerosis, Parkinson's disease, Lewy Body Disease, Pick's Disease, Huntington's Disease, or Progressive Supra Nuclear Palsy.~3. Undergoing any chemotherapy or radiation therapy for any tumor or carcinoma.~4. Diagnosis or previous history of type I or type II diabetes. Potential subjects with no history of diabetes will be referred to their PCP for a hemoglobin A1C test if they have not had one in the year prior to enrollment.~5. Diagnosis or previous history of psychiatric illness that in the investigator's opinion would affect the subject's ability to successfully participate in the study.~6. In the Investigator's opinion, subject would be unable to successfully participate in the study for any reason.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-Serine Gummy Arm (Type: ACTIVE_COMPARATOR): L-serine will be presented in gummies containing 1g serine each. Subjects randomized into the L-serine arm will take 15 grams of L-Serine (15 gummies containing 1g of L-serine) orally twice daily for 246 days after the initial ascending dose period to confirm tolerability of the dose.
- Placebo Gummy Arm (Type: PLACEBO_COMPARATOR): Placebo gummies containing no L-serine will be packaged in the same manner as that of the L-Serine gummy arm and be given to patients to take two times a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written, voluntary, informed consent given~* 18 years or older~* Speak and read English~* Extensive ulcerative colitis based upon endoscopy, histopathology, and clinical symptoms~* SCCAI Score \> 3~* Presence of diarrhea (3 or more bowel movements per 24 hours) AND grossly visible blood in stool~Exclusion Criteria:~* Serum creatinine \> 2.0 mg/dL~* Pregnant or breastfeeding~* Prior history of total or subtotal colectomy, or currently has an ostomy~* History or suspicion of Crohn's disease or Indeterminate colitis~* Diagnosis of any condition deemed by the investigator inhibiting completion of the trial~* Initiated therapy with or change in mesalamine dose within the last 4 weeks~* Change in azathioprine, 6-mercaptopurine, or cyclosporine within the last 8 weeks~* Currently taking or have used corticosteroids within the last 8 weeks~* Rectally administered mesalamine or steroids within the last 2 weeks~* Current or prior use of anti-TNF alpha agents within the last 8 weeks~* Experimental ulcerative colitis agents within the last 8 weeks~* Concomitant use of CYP3A4 activity inhibitor (e.g. ketoconazole, itraconazole, ritonavir, indinavir, erythromycin)~* Uncontrolled diabetes (HgA1c \> 8.0) within 1 year~* Unstable Coronary artery disease/Class III/IV CHF~* Decompensated cirrhosis (e.g. encephalopathy, renal failure, ascites, GIB)~* Any known infection requiring antibiotics~* Active Clostridium difficile infection~* COPD requiring home oxygen~* HIV/AIDS with CD4 \< 200 or AIDs-defining illnesses/infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Oral Budesonide and Rectal Hydrocortisone (Type: EXPERIMENTAL): See intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age~* active rheumatoid arthritis (DAS28-CRP\>3.2)~* refractory to one or more anti-TNF~* on stable treatment for RA for \>/=4 weeks~* evidence of erosive disease and/or synovitis in wrist and/or knuckles~Exclusion Criteria:~* active systemic or local infection~* previous or current history of any demyelinization process in central nervous system, pancytopenia or aplasic anaemia~* signs of immunodeficiency, HIV infection or tuberculosis~* contraindications to MRI, such as metal devices, claustrophobia, moderate or severe renal insufficiency, or allergy to contrast agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues